Alaunos Therapeutics (FRA:WEK) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Alaunos Therapeutics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Alaunos Therapeutics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Alaunos Therapeutics's long-term debt to total assets ratio declined from Dec. 2022 (0.03) to Dec. 2023 (0.00). It may suggest that Alaunos Therapeutics is progressively becoming less dependent on debt to grow their business.

Alaunos Therapeutics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Alaunos Therapeutics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alaunos Therapeutics LT-Debt-to-Total-Asset Chart

Alaunos Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.03

0.22

0.03

Alaunos Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.03	0.04	0.04	0.04	-

Alaunos Therapeutics LT-Debt-to-Total-Asset Calculation

Alaunos Therapeutics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	7.577
	=	0.00

Alaunos Therapeutics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	0	/	7.577
	=	0.00

Alaunos Therapeutics (FRA:WEK) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Alaunos Therapeutics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Alaunos Therapeutics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Alaunos Therapeutics (FRA:WEK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alaunos Therapeutics Inc (FRA:WEK) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

TCRT:USA

Address

8030 El Rio Street, Houston, TX, USA, 77054

Website

https://www.alaunos.com

Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.

Alaunos Therapeutics (FRA:WEK) Headlines

No Headlines